Skip to main content
PAS 2025 Meeting Main banner
Final Program


Schedule at a Glance
Icon Legend
Presentation Icons
Ticketed Event
Ticketed Event
Back

Nephrology

Nephrology 1

Pegcetacoplan for Adolescents With Complement 3 Glomerulopathy or Primary Immune Complex-Membranoproliferative Glomerulonephritis: VALIANT Phase 3 Placebo-Controlled Trial Subgroup Analysis

Friday, April 25, 2025
4:00pm – 4:15pm HST
Location:  Convention Center: 316 A
Bradley P.. Dixon, University of Colorado School of Medicine, Aurora, CO, United States; Marina Vivarelli, Bambino Gesù Children's Hospital, Rome Italy, Rome, Lazio, Italy; Gema Ariceta, Hospital Vall d' Hebron. Barcelona, Barcelona, Catalonia, Spain; Yael Borovitz, Schneider Children's Medical Center, Petah Tikva, Tel Aviv, Israel; Larry A. Greenbaum, Emory University School of Medicine, Decatur, GA, United States; Christoph Licht, The Hospital for Sick Children, Toronto, ON, Toronto, ON, Canada; Antonio Mastrangelo, Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano,, milan, Lombardia, Italy; Nabil Z. Melhem, Evelina London Children's hospital, London, England, United Kingdom; Naoya Fujita, Aichi Children’s Health and Medical Center, Obu, Aichi, Japan; Nicole Van de Kar, RADBOUDUMC, Nijmegen, Gelderland, Netherlands; Dean L. Wallace, Rmch Mft, Manchester, England, United Kingdom; Li Li, Apellis pharmaceuticals, Waltham, MA, United States; Luis López Lázaro, Swedish Orphan Biovitrum AG, Basel, Basel-Stadt, Switzerland; Johan Szamosi, Swedish Orphan Biovitrum AB, Stockholm, Stockholms Lan, Sweden; Carla M.. Nester, UNIV OF IOWA, Iowa City, IA, United States

    Presenting Author(s)

  • Bradley P. Dixon, MD

    Professor of Pediatrics and Medicine
    University of Colorado School of Medicine
    Aurora, Colorado, United States

Disclosure(s):
Bradley P. Dixon, MD: Alexion, Astra Zeneca Rare Disease (Ongoing) (Products/Services: Consultant); Apellis Pharmaceuticals (Ongoing) (Products/Services: Consultant, Research Support including clinical trials & the principal or named investigator); Arrowhead Pharmaceuticals (Terminated, January 1, 2023) (Products/Services: Consultant); Calliditas Therapeutics (Terminated, August 28, 2024) (Products/Services: Consultant); Novartis Pharmaceuticals (Ongoing) (Products/Services: Consultant, Research Support including clinical trials & the principal or named investigator); Roche Genentech Pharmaceuticals (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator)